Literature DB >> 15863157

The impact of molar pregnancy on psychological symptomatology, sexual function, and quality of life.

Rodney W Petersen1, Kim Ung, Cynthia Holland, Julie A Quinlivan.   

Abstract

BACKGROUND: Molar pregnancy is an unusual complication of pregnancy whereby abnormal placental tissue proliferates in the absence of a fetus. There is usually a protracted follow-up period where pregnancy is contra-indicated. Whilst the medical outcomes of the disease have been well explored, limited data have evaluated the impact on psychological symptomatology, sexual function, and quality of life.
METHODS: Institutional ethics approval and individual consent were obtained. All women listed on the hospital molar pregnancy register receiving active follow-up (n = 102) and a random sample of women who had been registered in the previous 30 years (n = 56) were sent a postal survey outlining the purpose of the study and an invitation to participate. Questionnaires included the Hospital Anxiety and Depression Scale (HADS), Satisfaction with Life Scale (SWLS), and Sexual History Form 12 (SHF-12).
RESULTS: The response rate was 54%. The key findings were that 60%, 55%, and 18% of women scored > or =10 on the total HADS, > or =8 on HADS-A, and >8 on HADS-D, respectively. The presence of children played a protective role and was associated with significantly better psychological function and quality of life. SWLS were in the lower end of ranges reported for community controls (mean of 23.9). Chemotherapy had an adverse impact on quality of life ratings (SWLS for chemotherapy yes = 21.7, no = 25). Sexual dysfunction was similar to community samples and was independent of age, time since diagnosis, chemotherapy requirement, and presence of children. Qualitative results complemented the quantitative data with similar emotional themes identified as well as issues related to the medical condition, care, and support networks.
CONCLUSION: Women with a molar pregnancy may benefit from a multidisciplinary approach to management that addresses their psychological and sexual needs in addition to medical aspects of care.

Entities:  

Mesh:

Year:  2005        PMID: 15863157     DOI: 10.1016/j.ygyno.2005.01.015

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Sexual function in women after surgery for pelvic organ prolapse.

Authors:  Mahyar Azar; Sima Noohi; Shokoufeh Radfar; Mohammad Hadi Radfar
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-06-15

2.  Ruptured tubal hydatidiform mole.

Authors:  Modupeola Omotara Samaila; Adebiyi Gbadebo Adesiyun; Calvin Bifam
Journal:  J Turk Ger Gynecol Assoc       Date:  2009-09-01

3.  Association of ß-hCG Surveillance with Emotional, Reproductive, and Sexual Health in Women Treated for Gestational Trophoblastic Neoplasia.

Authors:  Elizabeth L Jewell; Carol Aghajanian; Margaret Montovano; Sharyn N Lewin; Raymond E Baser; Jeanne Carter
Journal:  J Womens Health (Larchmt)       Date:  2017-12-21       Impact factor: 2.681

4.  An investigative study into psychological and fertility sequelae of gestational trophoblastic disease: the impact on patients' perceived fertility, anxiety and depression.

Authors:  Valentina E Di Mattei; Letizia Carnelli; Martina Bernardi; Elena Pagani Bagliacca; Paola Zucchi; Luca Lavezzari; Veronica Giorgione; Alessandro Ambrosi; Giorgia Mangili; Massimo Candiani; Lucio Sarno
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

5.  Mental Representations of Illness in Patients with Gestational Trophoblastic Disease: How Do Patients Perceive Their Condition?

Authors:  Valentina E Di Mattei; Letizia Carnelli; Martina Mazzetti; Martina Bernardi; Rossella Di Pierro; Alice Bergamini; Giorgia Mangili; Massimo Candiani; Lucio Sarno
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

6.  The psychological impact of gestational trophoblastic disease: a prospective observational multicentre cohort study.

Authors:  L J Blok; M M Frijstein; Y K Eysbouts; Jae Custers; Fcgj Sweep; Car Lok; P B Ottevanger
Journal:  BJOG       Date:  2021-08-10       Impact factor: 7.331

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.